You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma

    SBC: ONCOARENDI THERAPEUTICS LLC            Topic: NHLBI

    Approximatelymillion Americans suffer from asthmawhich leads to aboutdeaths per yearand is responsible for estimated annual total direct and indirect costs of $billionDespite the existing treatments for asthmapredominantly combinations of inhaledagonists and corticosteroidsCSsthere remains a significant unmet medical need for new therapies which address two key issuesapproximatelyof patients are i ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients

    SBC: Thetis Pharmaceuticals LLC            Topic: 300

    ABSTRACTThetis plans to investigate TPan innovative and potential first in class therapeutic agentas an oral therapy for the induction and maintenance of remission of intestinal inflammation symptoms in ulcerative colitisUCpatientsWhile the precise etiology of UC is unknownit is thought to result from an inappropriate inflammatory response to commensal gut bacteria in genetically susceptible indiv ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a hybrid transcatheter mitral valve replacement and repair device

    SBC: Dura LLC            Topic: NHLBI

    PROJECT SUMMARYMitral regurgitationMRis the most prevalent valvular heart disease in the U Saffecting approximatelyof the populationThere aremillion patients in the US with moderate to severe MR requiring treatmentHoweveronly approximatelypatients in the U Sundergo surgery for MR each year due to concerns about procedural complexity and patient safetyThere is great enthusiasm among the heart valve ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Administrative Supplement to Promote Diversity in Research and Development Small Businesses

    SBC: NEUROENE THERAPEUTICS INC            Topic: NINDS

    Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. IGF::OT::IGF SBIR Topic 314 Phase II- 3D Human Tumor Co-culture System for Accurate Prediction of Clinical Efficacy.

    SBC: KIYATEC, LLC            Topic: NCI

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds

    SBC: FirstString Research, Inc            Topic: NIDDK

    Project Summary/Abstract According to the ADA, 25.8 million children and adults have diabetes. Diabetics have an increased risk of complications such as heart disease and are prone to impaired wound healing. A major cause of morbidity and hospitalizationis diabetic foot ulceration (DFUs) that may result in infection, gangrene, amputations requiring prolonged hospitalization, costly treatments, an ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government